Translational medicine - A paradigm shift in modern drug discoveryand development: The role of biomarkers

Advances in Experimental Medicine and Biology

Volumn 655, Issue , 2009, Pages 1-12

  Day, Mark ^b   Rutkowski, J Lynn ^b   Feuerstein, Giora Z ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NATURAL PRODUCT; DRUG;

ARTICLE; DISEASE MARKER; DRUG DESIGN; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATIENT SELECTION; PHARMACODYNAMICS; PHARMACOGENOMICS; PHYSIOLOGICAL PROCESS; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; SCORING SYSTEM; THERAPEUTIC MISCONCEPTION; TRANSLATIONAL RESEARCH; VALIDATION PROCESS; CHEMISTRY; CLINICAL TRIAL; DRUG DEVELOPMENT; METABOLISM; METHODOLOGY; REVIEW;

BIOLOGICAL MARKERS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN;

EID: 77954240272     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1132-2_1     Document Type: Article

References (19)

1. Biomarker Definition Working Group. Biomarkers and surrogate biomarkers endpoints: preferred definitions and conceptual framework. Clin Pharmacol Theraputics 2001; 69:89-95.
2. Trusheim R. Ernst R, Berndt ER et al. Stratified medicine : strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery 2007; 6:287-293. (Pubitemid 46505879)
3. Feuerstein GZ . Rutkowski JL. Walsh FS et al. The role of translational medicine and biomarkers research in drug discovery and development. American Drug Discovery 2007 ; 2:23-28.
4. US Food and Drug Administration (FDA) report. Challenge and opportunity on the critical path to new medical products. http:www.fda.gov/oc/initiatives/ criticalpath/whitepaper.pdf (2004).
5. Zammit S, Allebeck P, David AS. A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression and other nonaffective psychoses. Arch Gen Psychiatry 2004; 61(4) :354-60. (Pubitemid 38451544)
6. Green ME Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.J Clin Psychiatry 2006; 67(10):e12.
7. Wynn JK. Green MF, Sprock J et al. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 2007; 95(1-3) :134-42. (Pubitemid 47313638)
8. Iritani S. Neuropathology of schizophrenia: A mini review. Neuropathology 2007; 27(6) :604-8. (Pubitemid 350045668)
9. Dorph -Perersen KA. Pierri JN. Perel JM et al. The influence of chronic exposure to antipsychotic medications on brain size before and alter tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuro Psycho Pharmacology 2005; 30(9) :1649-61. (Pubitemid 43086022)
10. Berry DA. Bayesian Clinical Trials. Nature Drug Discovery Reviews 2006; 5:27-36.
11. Gallo P, Chuang-Stein C, Dragalin V et al. Adaptive design in Clinical Drug Development- an executive summary of the PhRMA working group . Journal of Biopharmaceutical Statistics 2006; 16:275-283.
12. Krams M. Lees KR, Hacke W et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN). Stroke 2003; 34:2543-2548.
13. Kurzrock R. Studies in target -based treatment. Molecular Cancer Theraputics 2007; 6:1477.
14. Hampton T. Trials assess Myasthenia Gravis therapies .JAMA 2007; 298-1: 29-30. (Pubitemid 47026785)
15. Chien KR. Herceptin and the hean-a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789-790. (Pubitemid 43290916)
16. Hershey J, Steiner B. Fischli W et al. Renin Inhibitors: An antihypertensive strategy on the verge of reality. Drug Development Today 2005; 2:181-185. (Pubitemid 41488150)
17. Simmons D. What makes a good anti-inflammatory drug target? Drug Discovery and Development 2006; 5/6 :210-219.
18. Gombar C, Loh, E. Learn and Confirm. Drug Discovery and Development 2007; 10,22-27.
19. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharm Ther 2007; 61: 275-291.